Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

245

HTML

2203

Figures (1-3)

186

Tables (1-2)

172

Sum=2806

Apr 28, 2005 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Apr 28, 2005; 11(16): 2526-2529
Published online Apr 28, 2005. doi: 10.3748/wjg.v11.i16.2526

Table 1 Composition of the PIAF regimen.

¹Human recombinant α-INF-2a (Shanghai Roche Co.). Abbreviations: IV: intravenous; S.C.: subcutaneous; MU: million unit.

Citation: Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005; 11(16): 2526-2529
URL: https://www.wjgnet.com/1007-9327/full/v11/i16/2526.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i16.2526